Is Overall Sentiment on Eli Lilly and Company Bearish?

Eli Lilly and Company shares fell -1.9% this afternoon to a price of $454.25. The stock is still trading within range of its average target price of $456.1, and over the last 52 weeks, it has recorded a 4016.7% performance. Analysts have given the large-cap Pharmaceutical stock target prices ranging from $300.0 to $550.0 dollars per share, with an average rating of buy.

The stock has a very low short interest at 0.7%, and a short ratio of 2.16. The company's insiders own 0.15% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 84.0% of Eli Lilly and Company's shares being owned by this investor type.

Institutions Invested in Eli Lilly and Company

Date Reported Holder Percentage Shares Value
2023-03-31 Lilly Endowment, Inc 11% 102,543,810 $46,580,525,692
2023-03-31 Vanguard Group, Inc. (The) 7% 69,988,183 $31,792,132,127
2023-03-31 Blackrock Inc. 7% 65,571,525 $29,785,865,231
2023-03-31 PNC Financial Services Group, Inc. 5% 51,921,940 $23,585,541,245
2023-03-31 State Street Corporation 4% 33,236,143 $15,097,517,957
2023-03-31 FMR, LLC 3% 32,007,276 $14,539,305,123
2023-03-31 Capital World Investors 3% 27,588,540 $12,532,094,295
2023-03-31 Primecap Management Company 3% 25,367,550 $11,523,209,587
2023-03-31 Price (T.Rowe) Associates Inc 2% 22,722,734 $10,321,801,919
2023-03-31 Wellington Management Group, LLP 2% 20,324,267 $9,232,298,284

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Eli Lilly and Company.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.